Evidence boundary: This article reviews published, registered, analytical, preclinical, clinical, and regulatory sources involving the exact TB-500 fragment, full-length thymosin beta-4, related fragments, or product-specific formulations identified in each source. Findings involving full-length thymosin beta-4 or another derivative cannot be transferred automatically to TB-500 or to a separately manufactured material bearing that name. Nothing here is a claim about an FDB research product, a recommendation for human use, or medical advice. First Due Biotech products are offered strictly for laboratory research use only and are not for human consumption.
What is TB-500?
The best-supported product-specific definition of TB-500 is an N-terminally acetylated seven-amino-acid peptide: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, abbreviated Ac-LKKTETQ. It corresponds to residues 17–23 within the much larger endogenous protein thymosin beta-4.
Full-length mature human thymosin beta-4—also called Tβ4 or timbetasin—is a 43-amino-acid peptide encoded by the TMSB4X gene. It contains the LKKTETQ sequence, but also includes substantial N-terminal and C-terminal regions absent from TB-500.
The two molecules are related, not identical:
| Feature | TB-500 | Full-length thymosin beta-4 |
|---|---|---|
| Best-supported sequence | Ac-LKKTETQ | 43-amino-acid mature Tβ4 |
| Approximate molecular weight | 889.0 g/mol | 4,963.4 g/mol |
| Relationship | Acetylated 17–23 fragment | Endogenous full-length peptide |
| Direct human outcome evidence | No completed results identified | Several formulation-specific clinical programs |
| Evidence-transfer rule | Requires direct fragment evidence | Findings cannot be assigned to TB-500 automatically |
This identity distinction controls the entire evidence review. Much of the research popularly described as “TB-500 research” actually studied full-length Tβ4 in ophthalmic drops, dermal gels, systemic formulations, recombinant products, or animal models.
How TB-500 received its molecular definition
The earliest product-specific peer-reviewed analytical record identified a veterinary preparation that had appeared in racing settings. In 2012, investigators synthesized and characterized its principal peptide as N-terminally acetylated Tβ4(17–23), Ac-LKKTETQ.
Later anti-doping and metabolism research retained the same definition. A 2024 analytical study again described TB-500 as Ac-LKKTETQ while examining metabolism in serum, enzyme systems, and rats. FDA’s 2026 scientific review also used Ac-LKKTETQ-OH as the best-supported identity while documenting inconsistent nomination and marketplace descriptions.
These sources establish a defensible research definition. They do not prove that every material sold as TB-500 contains that sequence, acetylation state, salt form, purity, or quantity. The original 2012 analysis characterized one preparation, not the whole market.
Why researchers are interested in the Tβ4 fragment
Thymosin beta-4 is a major intracellular G-actin-binding peptide. By interacting with actin monomers, full-length Tβ4 participates in cytoskeletal regulation, cell migration, and tissue responses. Research programs have also examined angiogenesis, inflammation, extracellular-matrix remodeling, wound closure, corneal repair, and cardiac or neurological injury models.
The LKKTETQ region is important to Tβ4 biology. A 2003 experimental package reported that an LKKTETQ fragment and full-length Tβ4 produced similar endothelial-cell migration and chick-aortic sprouting responses under the tested conditions. A separate aged-mouse wound report described activity for the fragment that approximated the parent peptide.
Those studies provide a genuine fragment-to-parent bridge—but a narrow one. They did not establish that Ac-LKKTETQ reproduces every molecular interaction, tissue effect, pharmacokinetic feature, or safety characteristic of the 43-residue peptide.
Structural studies show why the boundary matters: full-length Tβ4 binds actin through distributed contacts involving residues beyond LKKTETQ. Sequence inclusion does not make a seven-residue fragment a complete substitute for the parent molecule.
Research at a glance
| Research area | What the identified evidence supports | Evidence assessment |
|---|---|---|
| TB-500 identity | Analytical and regulatory sources converge on Ac-LKKTETQ | Moderate to high for the intended research definition; marketplace identity remains uncertain |
| Relationship to Tβ4 | TB-500 contains the 17–23 motif but lacks most of the full-length peptide | Chemically established |
| Fragment migration and sprouting | LKKTETQ produced activity similar to full-length Tβ4 in a narrow endothelial/aortic-sprouting study | Direct but limited preclinical bridge |
| Direct TB-500 human outcomes | No completed clinical-outcome study of verified Ac-LKKTETQ was identified | Absent |
| Direct human PK and safety | No adequate verified-fragment dataset was identified | Absent |
| Full-length Tβ4 wound and ocular research | Multiple formulation-specific human programs produced tolerability and selected exploratory signals, with several missed primary endpoints | Relevant to Tβ4, not transferable to TB-500 |
| Full-length Tβ4 animal research | Broad migration, wound, ocular, cardiac, neurological, and vascular findings | Substantial parent-peptide evidence |
| TB-500 musculoskeletal research | One 2026 rat Achilles study named TB-500 but did not analytically define its commercial test article | Preliminary and identity-limited |
| Combination with BPC-157 | One small rat study found no additive advantage | No established synergy |
| Regulatory status | No therapeutic approval identified; FDA staff and the 2026 advisory committee reached different 503A recommendations | Dynamic and unresolved |
Actin binding and cell migration
Full-length Tβ4’s best-established molecular property is G-actin sequestration. Structural and mutational research indicates that the peptide wraps around actin and makes contacts through multiple regions. The LKKTETQ motif contributes materially to the interaction, but it is not the entire binding interface.
This makes simple statements such as “TB-500 works by binding actin exactly like thymosin beta-4” too strong. The full-length molecule has extensive direct structural evidence; the seven-residue fragment has narrower functional evidence.
The most relevant direct fragment study examined endothelial migration and sprouting. Under the selected experimental conditions, LKKTETQ and full-length Tβ4 produced similar responses. That result supports biological activity within the motif and provides a plausible basis for further fragment research.
It does not establish whole-organism tissue repair, dose equivalence, duration of action, or human benefit. Cell migration and vascular sprouting are mechanistic or surrogate endpoints, not completed tissue restoration.
Angiogenesis, inflammation, and matrix remodeling
Full-length Tβ4 has been studied in endothelial cells, skin wounds, corneal injury, ischemic tissue, and extracellular-matrix systems. Reported findings include cell migration, tube formation, re-epithelialization, collagen and matrix-metalloproteinase changes, and altered inflammatory signaling.
These pathways are scientifically coherent with repair biology. They also have context-dependent implications. Angiogenesis and cell motility can be helpful in some experimental repair settings while raising different questions in tumors, fibrosis, or abnormal vascular growth.
For verified Ac-LKKTETQ, the direct mechanistic package is much smaller. The fragment’s activity in selected migration and sprouting assays supports research interest but does not justify assigning the entire full-length wound or organ-repair literature to TB-500.
Musculoskeletal research and the 2026 Achilles study
TB-500 is commonly associated with tendon, ligament, and muscle research, yet direct fragment-specific evidence is sparse.
The principal paper explicitly naming TB-500 is a 2026 independent rat Achilles study that also evaluated BPC-157 and their combination. Investigators transected and surgically repaired Achilles tendons in 32 male rats, randomized the animals into four groups, and used coded biomechanical samples and blinded histopathology.
The TB-500 group showed a statistically significant increase in maximum load to failure compared with controls in a very small biomechanical branch. It also showed better total Bonar and Movin histopathology scores and selected collagen-organization differences. The combination group did not show a superior or additive result.
This is a worthwhile preclinical signal because it used a repaired tendon model and included both mechanical and histological endpoints. Its interpretation is limited by several factors:
- Only four tendons per group were assigned to biomechanical testing and four to histology.
- Outcomes were measured at one four-week time point.
- The study used young healthy male rats.
- The commercial test article’s sequence, molecular mass, acetylation state, purity, and chromatogram were not reported.
- No verified Ac-LKKTETQ or full-length comparator was included.
The paper therefore supports further study of the material used in that rat experiment. It does not independently establish that chemically verified TB-500 restores human tendon strength or that combining it with BPC-157 provides added benefit.
Other frequently cited musculoskeletal studies used full-length Tβ4, unspecified Tβ4 material, or undefined fragments. For example, long-term full-length Tβ4 research in an mdx mouse model reported a histologic regeneration signal but no improvement in grip strength, Rotarod performance, or echocardiographic function.
Wound and skin research
Full-length Tβ4 has a broad preclinical wound literature. Rodent studies have reported changes in wound closure, re-epithelialization, collagen, matrix remodeling, inflammatory cells, and vascularization.
Human dermal development used full-length Tβ4 gel, known as RGN-137—not TB-500. Trials examined venous stasis ulcers, pressure ulcers, and epidermolysis bullosa. These studies generally supported short-term tolerability and produced selected exploratory closure signals, but definitive efficacy was not established.
The venous-ulcer program reported an exploratory signal for one concentration, with safety as the principal objective. Pressure-ulcer and epidermolysis-bullosa trials did not establish statistically significant healing efficacy, and one later study terminated after only a few participants.
These programs show that full-length Tβ4 reached genuine human clinical research. They do not validate Ac-LKKTETQ, establish equivalence between formulations, or supply a human TB-500 safety record.
Eye and corneal research
Full-length Tβ4 ophthalmic drops, developed as RGN-259, have been studied in dry eye and neurotrophic keratopathy.
Dry-eye trials produced favorable secondary, pooled, or time-specific findings in some analyses, but repeatedly failed one or more prespecified co-primary endpoints. In neurotrophic keratopathy, the small SEER-1 trial reported a large numerical difference in complete healing that did not reach statistical significance at the primary time point; a later follow-up favored the active group. The larger SEER-3 program also missed its primary healing endpoint according to the available sponsor report.
This is a meaningful full-length Tβ4 research program because it includes controlled human exposure and objective ocular endpoints. The mixed results also show why trial hierarchy matters: secondary or later time-point signals cannot convert a missed primary endpoint into a successful pivotal trial.
None of these ophthalmic findings can be described as evidence that TB-500 improves eye or tissue repair. RGN-259 contains full-length Tβ4 in a formulation and route specific to the ocular program.
Cardiac and neurological research
Full-length or recombinant Tβ4 has generated substantial animal research in cardiac ischemia, vascular recovery, stroke, traumatic brain injury, multiple sclerosis models, and peripheral neurological injury.
Some programs reported functional improvements in animal cardiac or neurological endpoints. Other influential findings did not replicate cleanly. Independent lineage-tracing work challenged a proposed conversion of epicardial-derived cells into cardiomyocytes, a knockout study contradicted claims that Tβ4 was indispensable for vascular development, and a pig global ischemia-reperfusion study was null.
Human systemic programs also concern different entities. RGN-352 was a planned full-length Tβ4 cardiac trial that enrolled no participants. Recombinant Tβ4 product NL005 reached human studies and showed short-term tolerability in healthy volunteers. Its Phase IIb myocardial-infarction trial did not significantly improve the overall prespecified infarct-size endpoint, although selected secondary measures and a treatment-timing subgroup appeared favorable.
These findings remain relevant to the scientific development of full-length Tβ4. They are not evidence for Ac-LKKTETQ TB-500.
What human evidence exists for verified TB-500?
No completed human clinical-outcome study of chemically verified Ac-LKKTETQ was identified through the evidence cutoff.
FDA’s 2026 review found no human clinical, exposure, pharmacokinetic, pharmacodynamic, or effectiveness study for the nominated TB-500 material. No peer-reviewed human case report with analytically confirmed exposure was identified.
The first located prospective registry explicitly naming the Tβ4 17–23 fragment is TBRIDGE-CV, NCT07487363. The study is investigating cardiovascular biomarkers in stable atherosclerotic cardiovascular disease. It had no public results through the cutoff.
This means the direct human evidence classification is straightforward:
- Human efficacy: not established
- Human pharmacokinetics: not established
- Human pharmacodynamics: not established
- Human adverse-event incidence: not established
- Long-term safety: not established
Human results involving RGN-259, RGN-137, RGN-352, NL005, or Ac-SDKP belong to different molecules or formulations and cannot fill these gaps.
Pharmacokinetics and metabolism
Analytical anti-doping research has examined TB-500 and its metabolites in animal, serum, and enzyme systems. These studies help identify degradation products and improve detection methods.
They do not provide a validated human therapeutic half-life. No adequate human absorption, bioavailability, distribution, intact-fragment half-life, clearance, tissue exposure, or excretion dataset was identified for Ac-LKKTETQ.
Values reported for full-length Tβ4 cannot be transferred automatically. Molecular size, terminal modifications, protease susceptibility, actin interactions, formulation, and route can all change disposition.
Claims that TB-500 has a long “functional half-life,” accumulates in tissue for days, or shares the parent peptide’s pharmacokinetics therefore remain unverified for the exact fragment.
Safety and tumor-relevant questions
No adequate direct safety package was identified for verified TB-500. Missing elements include controlled human safety, repeat-dose toxicology, safety pharmacology, genotoxicity, reproductive and developmental toxicology, carcinogenicity, and robust immunogenicity assessment.
Full-length Tβ4 and recombinant-product studies provide some short-term formulation-specific human tolerability information. They cannot establish the safety of a smaller acetylated fragment or a separately manufactured material.
Migration, angiogenesis, and epithelial-to-mesenchymal-transition pathways create a reasonable tumor-promotion question. The evidence is not one-directional: most studies involve endogenous expression, genetic manipulation, tumor-cell models, or full-length Tβ4, and some systems report opposing effects. No identified evidence demonstrates that TB-500 causes human cancer.
The correct conclusion is uncertainty, not reassurance or alarm. Direct fragment-specific tumor and long-term safety research is missing.
Material quality adds a separate risk domain. A label cannot establish sequence, N-terminal acetylation, salt or counter-ion, related-peptide impurities, aggregation, residual synthesis materials, endotoxin, bioburden, sterility, particulates, or actual content. Lot-specific orthogonal analytical testing is essential to any credible laboratory interpretation.
Regulatory and anti-doping context
No FDA-, EMA-, Health Canada-, or TGA-approved therapeutic product containing TB-500 was identified.
FDA staff’s 2026 scientific review recommended against placing the nominated TB-500 substance on the Section 503A Bulks List, citing identity, effectiveness, safety, and characterization gaps. In July 2026, the Pharmacy Compounding Advisory Committee reached the opposite nonbinding recommendation and voted in favor of listing.
Neither the staff recommendation nor the advisory committee vote is drug approval. The committee advises FDA; final regulatory action requires a separate agency process. This split should be stated plainly rather than simplified into “FDA approved,” “FDA banned,” or “now legal for human use.”
The World Anti-Doping Agency’s 2026 Prohibited List names thymosin beta-4 and its derivatives, including TB-500, as prohibited at all times. Racing authorities also monitor TB-500 and related metabolites.
Regulatory status and sports rules can change and should be rechecked immediately before publication.
Why the evidence remains scientifically important
TB-500 sits at an interesting boundary between fragment pharmacology and parent-peptide biology. The LKKTETQ region has demonstrated activity in selected migration and sprouting assays, while full-length Tβ4 has a coherent and extensive literature involving actin, cell movement, wound responses, ocular research, and organ-injury models.
The opportunity for future research is to determine which parent-peptide functions survive fragment reduction, which require the missing sequence regions, and how N-terminal acetylation changes stability or signaling.
The 2026 rat Achilles study provides an encouraging direct research direction but also illustrates the need for exact test-article characterization. A positive biological result cannot be assigned confidently to Ac-LKKTETQ when the material’s sequence and mass were not reported.
A stronger evidence program would include independently verified fragment identity, direct comparison of Ac-LKKTETQ with unacetylated LKKTETQ and full-length Tβ4, modern actin-binding and signaling assays, quantitative animal PK, repeat-dose toxicology, preregistered musculoskeletal studies, and transparent prospective human research where legally and ethically authorized.
The most evidence-aligned conclusion is specific and still positive: TB-500 is a defined Tβ4-derived research fragment with direct activity in limited preclinical systems and a compelling relationship to full-length Tβ4 biology. Its human efficacy, pharmacokinetics, and safety remain unestablished, and the broader Tβ4 literature should be treated as context rather than fragment proof.
Key takeaways
- The best-supported identity for TB-500 is Ac-LKKTETQ, an acetylated seven-residue Tβ4(17–23) fragment.
- Full-length thymosin beta-4 is a 43-amino-acid endogenous peptide and is not chemically identical to TB-500.
- LKKTETQ showed activity similar to full-length Tβ4 in a narrow endothelial-migration and aortic-sprouting experiment.
- Distributed full-length Tβ4–actin contacts prevent assuming complete functional equivalence.
- No completed human clinical-outcome, PK, PD, or adequate safety study of verified TB-500 was identified.
- Human eye, wound, cardiac, and tolerability studies involved full-length or recombinant Tβ4 products, not TB-500.
- A 2026 rat Achilles study reported favorable TB-500-group biomechanical and histological findings, but the commercial test article was not analytically defined.
- The same study did not establish additive benefit from combining TB-500 with BPC-157.
- FDA staff recommended against 503A listing while the advisory committee voted in favor; neither action constituted approval.
- WADA prohibits thymosin beta-4 and its derivatives, including TB-500, at all times.